Compare Merck & Co., Inc. (MRK) vs iShares 0 3 Month Treasury Bond ETF (SGOV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs iShares 0 3 Month Treasury Bond ETF — how do they compare? Merck & Co., Inc. trades at $148.15 (market cap $366.28B), while iShares 0 3 Month Treasury Bond ETF trades at $100.5. The key difference: Merck & Co., Inc. pays a 2.29% dividend while iShares 0 3 Month Treasury Bond ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, iShares 0 3 Month Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| MRK | SGOV | |
|---|---|---|
Market Cap | $366.28B | — |
Sector | Health | Fixed Income |
52-Week High | $156.43 | $100.72 |
52-Week Low | $77.60 | $100.28 |
Enterprise Value | $413.04B | — |
Dividend Yield | 2.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MRK trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and support near $147. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.22. Revenue reached $65.01B in 2025, and the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline.
Outlook remains positive with a consensus price target of $157, offering ~6% upside. Risks include high P/E of 118.77 and competitive pressures in pharma. Institutional buying and a 67.57% buy rating from analysts support a constructive view, though net income margin of 4.77% warrants monitoring.
SGOV trades at $100.475 with minimal daily movement, showing price stability amid bearish technical signals. The ETF maintains consistent dividend distributions with recent payouts of $0.30-$0.31 per share. Technical indicators show strong bearish momentum with 17 sell signals versus 3 buy signals, though RSI levels suggest potential oversold conditions. Market sentiment reflects broader Treasury market concerns as rising oil prices fuel inflation worries.
The outlook remains cautious given the bearish technical picture and macroeconomic headwinds from rising Treasury yields. Investors seeking Treasury exposure may find value in SGOV's stability and dividend consistency, though the current environment of rising rates and inflation pressures presents near-term challenges for fixed income ETFs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About iShares 0 3 Month Treasury Bond ETF
SGOV provides exposure to ultra-short-term U.S. Treasury bills with maturities of three months or less. It functions as a high-liquidity cash alternative, seeking to provide current income while maintaining a stable net asset value and minimal interest rate risk.
Read more on SGOV →
